Member Info for HarChris

If it’s all so easy you must be doing that BV and hence it’s a bit hypocritical complaining of others (at least in your head) doing the same?

That’s such utter nonsense to say ‘no prospect of good news for at least a couple of months’ - how about near complete response on the patient we were informed had seen a partial response? What about the third party warhead partnership that was mooted by management a few months ago? What about ODD approval?

No one knows for sure if we’ll have good news soon besides the management but to say there’s no prospect of good news is total BS this far into 1b.

Many said the same recently but it’s up 50% since - perhaps they are just wrong?

Yeah I agree although tangible progress absolutely has to be made by the end of this year if GRL are to have a strong negotiation position with AIMSL re the maturing gold loan. It's not enough to stroll towards Dec 31st. there has to have been a step up in production by then so there's still time but it is (slowly) running out.

I don’t think I’ve ever seen such consistently excellent communication from a small cap explorer before. Bravo.

Down day and people claim the flippers have sold. Up day and there’s a huge buyer in town. Rinse and repeat.

Truth is no one knows so if you’re a long term holder switch off, and wait for far higher once more news lands.

Down day and people claim the flippers have sold. Up day and there’s a huge buyer in town. Rinse and repeat.

Truth is no one knows so if you’re a long term holder switch off, should be far higher once more news lands.

NAV does not account for future cash flows, something that THX is absolutely swimming in right now. Just look at the most recent financial accounts, Q1, NAV increased $36m.

So whilst current NAV according to Q1 is $238m that will start rocketing $40m/Q or $160m per year just for Segilola 'til EOM.

There's still a huge value disconnect here if you expect strong economics from Douta, mine life extension at Segilola and eventually additional cash flows from the highly promising Ivory Coast assets.

The Douta PFS alone will almost certainly show a NPV that far exceeds the current market cap.

Actually it’s up 21p since you were trolling this bb a few weeks ago, not ‘a few p’.

Well I was right in as much as only seeing a tad lower without an RNS (vs your sub 3p) but not great all in all.

Fingers crossed for positivity from this upcoming meeting.

What happens in the oncology space over the next five to ten years will obviously affect the top end valuation for AVCT but not worth quibbling about until the valuation here is multiples of this paltry £200m mcap.

So for now I’d say there are no competitors that could rip up the investment case today.

This is about as good as we could hope for at this stage. The share price has weakened recently due to the clear need for further fundraising by the end of the year but management delivered a stronger H2 as promised and have been winning new contracts of late so it's a case of trusting them to secure that next lot of funding on preferable terms and then the path forward is clear.

I don’t but it will probably fall a tad more.

There is obviously something to discuss, even if financing isn’t completely over the line. I don’t see the pre-arranged IMC as anything other than a positive, even if it’s not quite as positive as we all want right now (funding sorted).

Well we know they certainly aren’t selling en masse, that’s a fact. If market makers were trying to sell 10m shares from all those placees the share price would show continued weakness right back down into the 30s but instead we’re looking more likely to be back on the 50s.

Impossible to know if some placees sold a few at the top but we can say with certainty that they aren’t dumping like Heights would have been. And that makes it light and day at a bare minimum.

It's total BS. After a near 100% rise (touching 60p last week) the share price has retraced off the back of just 5-10m total volume.

There will be loads of overexposed PIs tempted to sell a few after such a rise so we have absolutely no idea who has sold over the past few sessions.

Not true at all. The quarterly downward pressure on Heights overshadowed all potential news and put a hard brake on each and every rise.

A partnership with a third party's warhead was discussed by CC at the AGM one month ago and hinted at being close, that couldn't have been seen 3 or 4 months ago.

The doubling of the PFS in SGC required more time, so couldn't have been said 3 or 4 months ago as a very near term rns.

The short wasn't closing 3 or 4 months ago.

The p1b trial had barely begun 3 or 4 months ago so partial responses being announced at any time couldn't have been said then, either.

All mega moves see numerous retraces and pullbacks along the way.

That's your opinion but I think it's nonsense. This is the first time there is no expectation of a payment to Heights so no reason to see fear as we get close to late Oct (which is ages away right now) - and there is plenty of potential news between now and then (More partial responses, ODD in SGC, announcement of a doubling of PFS in SGC, partnership with third party warhead). And we've just seen GSA reduce their short so that alone has the potential to drive the next leg up.

Others feel there’s more than enough news likely before then (Oct 21st) to see the share price far higher and hence the small placing still being above today’s 50p.

If there was going to be a large 40p placing to extend the runway then they would almost certainly have paid the last Heights issuance in cash, let the share price run and then done a larger raise at 40p. The plan has always been to tie the next big funding round with the 1b data, something that at least requires a large SGC dataset. We're close to that so why on earth would they raise prior to groundbreaking news when it's so close?

I imagine next we see a partnership deal using a third party warhead and that is this external validation the market's been crying out for. Follow that up with ODD for SGC, perhaps more partial responses and then work the larger funding package alongside data readout at the back end of this year.

It sounds simple but if the data is as compelling as we hope then at this stage it should be relatively simple to execute.